Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection

Affiliations

Editorial

Niels Steinebrunner et al. J Thorac Dis. 2018 Jan.

. 2018 Jan;10(1):118-120.

doi: 10.21037/jtd.2017.12.117.

¹ Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group. Vickers RJ, et al. Lancet Infect Dis. 2017 Jul;17(7):735-744. doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28. Lancet Infect Dis. 2017. PMID: 28461207 Free PMC article. Clinical Trial.

1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36. 10.1038/nrmicro2164 - DOI - PubMed
1. Vonberg RP, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis 2007;13:179-80. 10.3201/eid1301.060611 - DOI - PMC - PubMed
1. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013;45:109-13. 10.1038/ng.2478 - DOI - PMC - PubMed
1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-34. 10.1056/NEJMoa1408913 - DOI - PMC - PubMed
1. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008;359:1932-40. 10.1056/NEJMra0707500 - DOI - PubMed